Incyte Corporation
INCY Healthcare Biotechnology
Incyte Corporation’s revenue for fiscal 2025 (year ended December 2025) was $5.1 billion, up 21.2% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 39.7%, free cash flow grew 1,829.5% and total debt fell 10.5%, each against the same quarter a year earlier. Member of the S&P 500; revenue growth for ten consecutive years.
Follow INCY
Incyte Corporation (INCY) Total debt
Incyte Corporation's total debt at the end of fiscal 2025 was $30.2M, down 9.97% from $33.5M in fiscal 2024. At the end of the quarter to 30 June 2026 it was $28.4M. Over the past ten years it has ranged from $17.4M (fiscal 2018) to $651.5M (fiscal 2016); the current reading is higher than 45% of that period. Incyte Corporation ranks 175th of 593 Biotechnology companies by total debt.
Total debt, annual
Embed this chart
Annual newest first
| Period | Total debt | Change |
|---|---|---|
| FY2025 | $30.2M | (9.97%) |
| FY2024 | $33.5M | 15.02% |
| FY2023 | $29.2M | (3.06%) |
| FY2022 | $30.1M | (4.90%) |
| FY2021 | $31.6M | (2.89%) |
| FY2020 | $32.6M | (35.14%) |
| FY2019 | $50.2M | 188.05% |
| FY2018 | $17.4M | (27.36%) |
| FY2017 | $24.0M | (96.32%) |
| FY2016 | $651.5M | 5.10% |
Quarterly newest first
| Period | Total debt | Change |
|---|---|---|
| Jun 2026 | $28.4M | (3.38%) |
| Mar 2026 | $29.4M | (2.60%) |
| Dec 2025 | $30.2M | (2.21%) |
| Sep 2025 | $30.9M | (2.77%) |
| 42 more quarters | Free account |
Against its own ten years
Total debt against peers
| Company | Total debt |
|---|---|
| RPRX Royalty Pharma PLC compare | $9.0B |
| GMAB Genmab A/S Sponsored ADR compare | $5.1B |
| ALNY Alnylam Pharmaceuticals, Inc. compare | $1.0B |
| INSM Insmed, Inc. compare | $562.4M |
| ASND Ascendis Pharma A/S compare | $523.3M |
| BNTX BioNTech SE Sponsored ADR compare | $367.5M |
| ROIV Roivant Sciences Ltd. compare | $323.7M |
| EXEL Exelixis, Inc. compare | $191.0M |
| INCY Incyte Corporation | $28.4M |
What Total debt is
Total Debt tells an investor how much a company has borrowed in all, whether the money is due within a year or later.
Long Term Debt (Total) + Current Part of Debt
More on INCY
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement